Unternehmen wird geladen
Keep exploring
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T $A+
JNJJohnson & Johnson688,6B $A+
MRKMerck & Co., Inc.364,3B $A
NVSNovartis AG306,3B $A
AMGNAmgen Inc.251,9B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Sales of prescription medicines
- Revenue from medicine partnerships
Konkurriert mit
Was es verkauft6
Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
3 weitere anzeigen
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
Wer es kauft3
- Patients receive the medicines, usually after a clinician prescribes them.
- Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
- Government health systems and private insurers may pay for or reimburse medicines.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
- 2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
- 3Sales in China are affected by government volume-based purchasing and reimbursement decisions.
Was schiefgehen könnte
- 1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
- 2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
- 3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.
Über Astrazeneca plc
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
- Hauptsitz
- Cambridge, England, United Kingdom
- Gegründet
- 1992
- Notiert an
- New York Stock Exchange
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Astrazeneca plc bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.